AR062762A1 - METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS - Google Patents

METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS

Info

Publication number
AR062762A1
AR062762A1 ARP070104033A ARP070104033A AR062762A1 AR 062762 A1 AR062762 A1 AR 062762A1 AR P070104033 A ARP070104033 A AR P070104033A AR P070104033 A ARP070104033 A AR P070104033A AR 062762 A1 AR062762 A1 AR 062762A1
Authority
AR
Argentina
Prior art keywords
leaks
methods
protein
nucleic acid
subject
Prior art date
Application number
ARP070104033A
Other languages
Spanish (es)
Inventor
Richard J Gregory
Jiang Canwen
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR062762A1 publication Critical patent/AR062762A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Moléculas de ácidos nucleicos recombinantes codificantes de proteínas transactivadoras quiméricas y su uso para promover la vascularizacion colateral sin fugas. Métodos de tratamiento de trastornos caracterizados por un aumento de la permeabilidad vascular. Reivindicacion 1: Un método de tratamiento de la diabetes en un sujeto consistente en administrar al sujeto una cantidad efectiva de una molécula de ácido nucleico codificante de una proteína transactivadora quimérica biologicamente activa que contiene: (a) el dominio de union a ADN de una proteína de factor inducible por hipoxia y (b) un dominio proteico capaz de activacion transcripcional.Recombinant nucleic acid molecules encoding chimeric transactivating proteins and their use to promote collateral vascularization without leaks. Methods of treatment of disorders characterized by an increase in vascular permeability. Claim 1: A method of treating diabetes in a subject consisting of administering to the subject an effective amount of a nucleic acid molecule encoding a biologically active chimeric transactivator protein containing: (a) the DNA binding domain of a protein of hypoxia-inducible factor and (b) a protein domain capable of transcriptional activation.

ARP070104033A 2006-09-12 2007-09-12 METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS AR062762A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82539606P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
AR062762A1 true AR062762A1 (en) 2008-12-03

Family

ID=39060222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104033A AR062762A1 (en) 2006-09-12 2007-09-12 METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS

Country Status (2)

Country Link
AR (1) AR062762A1 (en)
WO (1) WO2008033304A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069760A1 (en) * 2014-10-31 2016-05-06 Steven Yu Method of treating dementia by intranasal administration of vegf gene therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use

Also Published As

Publication number Publication date
WO2008033304A2 (en) 2008-03-20
WO2008033304A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
EA200870594A1 (en) BINDING HUMAN MOLECULES WITH KILLER ACTIVITY AGAINST ENTEROCCOKKKI AND THEIR APPLICATION
DK2231860T3 (en) Polypeptide derived protein A and capable of binding PDGF
Marchetti et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV
RU2008136324A (en) GASTROINTESTINAL PROLIFERATIVE FACTOR AND ITS APPLICATIONS
EA200700391A1 (en) COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1
ATE536369T1 (en) ESSENTIALLY PH-INDEPENDENT AMINO ACID SEQUENCES BINDING TO SERUM PROTEINS, COMPOUNDS CONTAINING SAME, AND THEIR USE
ATE524546T1 (en) USE OF ANTI-TNF OR ANTI-IL1 RNAI TO SUPPRESS THE EFFECTS OF PRO-INFLAMMATORY CYTOKINE FOR LOCAL PAIN TREATMENT
ATE256186T1 (en) USES OF ANGIOGENIC FACTOR VEGF145 IN THE TREATMENT OF CARDIOVASCULAR DISEASES
ATE368054T1 (en) COMPOUNDS AND METHODS FOR MODULATING OCCLUDIN-DEPENDENT TISSUE PERMEABILITY
AR046682A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS
JP2012503026A5 (en)
RU2019119609A (en) PEPTIDS ABLE TO REACTIVATE P53 MUTANTS
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
ATE556728T1 (en) TISSUE STRUCTURES WITH HOMINING FACTORS
EA200600561A1 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF SHOCK
JP2021531038A5 (en)
CY1114747T1 (en) CHEMISTRY OF PHAGE POLYMERIZATION DNA Φ 29
MX2021014601A (en) Recombinant fap binding proteins and their use.
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
AR062762A1 (en) METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS
EA200501711A1 (en) FAMILY OF SECRETABLE PROTEINS
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
EA201200182A1 (en) BINDING HUMAN MOLECULES WITH KILLER ACTIVITY AGAINST ENTEROCCOKKKI AND THEIR APPLICATION
ATE512983T1 (en) RECEPTOR FOR THE TGR3-LIKE PROTEIN

Legal Events

Date Code Title Description
FB Suspension of granting procedure